Benzinga | Jun 16, 2021 01:13PM EDT

JMP Securities Maintains Market Outperform on Altimmune, Raises Price Target to $53

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and raises the price target from $45 to $53.JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and raises the price target from $45 to $53.